Evidence map›Paper›PMID 41298809›Full record

ArticleCommunications biology2025

Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-μSim framework.

Athanasios Grigoriou, Carlos Macarro, Marco Palombo, Daniel Navarro-Garcia, Anna Kira Voronova, Kinga Bernatowicz, Ignasi Barba, Alba Escriche, Emanuela Greco, María Abad and 15 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Athanasios GrigoriouVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Carlos MacarroVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID http://orcid.org/0009-0000-0597-9316
Marco PalomboCardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom.ORCID http://orcid.org/0000-0003-4892-7967
Daniel Navarro-GarciaVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Anna Kira VoronovaVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID http://orcid.org/0009-0006-9600-0436
Kinga BernatowiczVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Ignasi BarbaVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9886-3776
Alba EscricheVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Emanuela GrecoVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
María AbadVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Sara SimonettiVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Garazi SernaVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2666-0982
Richard MastInstitut de Diagnostic per la Imatge (IDI), Barcelona, Spain.
Xavier MerinoInstitut de Diagnostic per la Imatge (IDI), Barcelona, Spain.
Núria RosonInstitut de Diagnostic per la Imatge (IDI), Barcelona, Spain.
Manuel EscobarInstitut de Diagnostic per la Imatge (IDI), Barcelona, Spain.
Maria VieitoMedical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Paolo NuciforoVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Rodrigo ToledoVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Elena GarraldaMedical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Roser Sala-LlonchDepartment of Biomedicine, Faculty of Medicine, Institute of Neurosciences, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3576-0475
Els FieremansBernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1384-8591
Dmitry S NovikovBernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-4213-3050
Raquel Perez-Lopez *Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. rperez@vhio.net.ORCID http://orcid.org/0000-0002-9176-0130
Francesco Grussu *Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. fgrussu@vhio.net.ORCID http://orcid.org/0000-0002-0945-3909

Funding

TR&D 4: Revealing Microstructure: Biophysical modeling and validation for discovery and clinical careP41EB017183 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Daniel K Sodickson · 2014 to 2026
$19.3M
AstraZeneca PREdICTBanco Bilbao Vizcaya Argentaria (BBVA) 89/2017Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) 2019 BP 00182Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) 2023PROD00178EC | Directorate-General for Employment, Social Affairs and Inclusion | European Social Fund (Fondo Social Europeo) A way to make EuropeEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 801370Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) PRYCO211023SERR"la Caixa" Foundation (Caixa Foundation) CaixaResearch Advanced Oncology"la Caixa" Foundation (Caixa Foundation) LCF/BQ/PR22/11920010Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) CEX2020-001024-S / AEI / 10.13039 / 501100011033Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PRE2022-102586Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI18/01395Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI21/01019NIBIB NIH HHS P41 EB017183Prostate Cancer Foundation (PCF) 18YOUN19
6 · The paper itself

Abstract

Diffusion Magnetic Resonance Imaging (dMRI) simulations in geometries mimicking the microscopic complexity of human tissues enable the development of innovative biomarkers with unprecedented fidelity to histology. Simulation-informed dMRI has traditionally focussed on brain imaging, and it has neglected other applications, as for example body cancer imaging, where new non-invasive biomarkers are still sought. This article fills this gap by introducing a Monte Carlo diffusion simulation framework informed by histology, for enhanced body dMR microstructural imaging: the Histo-μSim approach. We generate dictionaries of synthetic dMRI signals with coupled tissue properties from virtual cancer environments, reconstructed from hematoxylin-eosin stains of human liver biopsies. These enable the data-driven estimation of properties such as the intrinsic extra-cellular diffusivity, cell size or cell membrane permeability. We compare Histo-μSim to metrics from well-established analytical multi-compartment models in silico, on fixed mouse tissues scanned ex vivo (kidneys, spleens, and breast tumours) and in cancer patients in vivo. Results suggest that Histo-μSim is feasible in clinical settings, and that it delivers metrics that more accurately reflect histology as compared to analytical models. In conclusion, Histo-μSim offers histologically-meaningful tissue descriptors that may increase the specificity of dMRI towards cancer, and thus play a crucial role in precision oncology.

Indexed as

Diffusion Magnetic Resonance ImagingNeoplasmsAnimalsBreast NeoplasmsComputer SimulationFemaleHumansMiceMonte Carlo Method

Identifiers

PMID41298809
PMCPMC12657972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.